Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) Revenue
Annual & quarterly revenue history · segment & region breakdown
IOVA · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsIovance Biotherapeutics, Inc. trailing twelve-month (TTM) revenue is $0.29B, an increase of 60.60% year-over-year from $0.26B in FY2025.
Revenue trend
2025 – 2008 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.26B | +$0.10B | +60.60% |
| 2024-12-31 | $0.16B | +$0.16B | +13698.99% |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare IOVA revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Iovance Biotherapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Iovance Biotherapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Iovance Biotherapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IOVA revenue · 4 questionsIOVA's trailing twelve-month (TTM) revenue is $0.29B. That is an increase of 60.60% year-over-year from $0.26B in FY2025.
▸ Source: FMP · Iovance Biotherapeutics, Inc. SEC filings · GAAP · Iovance Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026